Background Patients with cancer have a substantial risk of recurrent thrombosis despite the
use of oral anticoagulant therapy. We compared the efficacy of a low-molecular-weight …

Background The use of warfarin sodium for treating venous thromboembolism in patients
with cancer is associated with a significant risk of recurrence and bleeding. The use of low …

Purpose Experimental studies and indirect clinical evidence suggest that low molecular
weight heparins may have antineoplastic effects. We investigated the influence of a low …

PURPOSE: A substantial clinical need exists for an alternative to vitamin K antagonists for
treating deep-vein thrombosis in cancer patients who are at high risk of both recurrent …

In this issue of the Journal, Lee et al., on behalfof the Randomized Comparison of Low-
Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of …

This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in
secondary prevention of venous thromboembolic events in adults with active malignancy …

Venous thromboembolism is a major complication in cancer patients. The basis for the
strong association between cancer and thrombosis remains incompletely understood, and …

Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …

Background: Cancer patients with venous thromboembolism (VTE) are at high risk of
recurrent VTE despite standard anticoagulation. To date, very little published literature is …

Cancer and its treatments are well-recognized risk factors for venous thromboembolism
(VTE). Evidence suggests that the absolute risk depends on the tumor type, the stage or …